Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.
about
Novel Therapies for Eosinophilic DisordersThe Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic TumorigenesisInterleukin-13 Activates Distinct Cellular Pathways Leading to Ductular Reaction, Steatosis, and FibrosisMechanosignaling through YAP and TAZ drives fibroblast activation and fibrosisIRAK-M promotes alternative macrophage activation and fibroproliferation in bleomycin-induced lung injury.Chitinase 3-like-1 and its receptors in Hermansky-Pudlak syndrome-associated lung disease.Aerobic Exercise Attenuated Bleomycin-Induced Lung Fibrosis in Th2-Dominant Mice.A protective role for IL-13 receptor α 1 in bleomycin-induced pulmonary injury and repairSustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways.Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-γTargeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?IL-13 is a therapeutic target in radiation lung injury.Facts and promises on lung biomarkers in interstitial lung diseases.A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.Immune Mechanisms in Pulmonary Fibrosis.The path to personalized medicine in asthma.Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update.Interleukin-13 promotes expression of Alix to compromise renal tubular epithelial barrier function.Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.New treatment directions for IPF: current status of ongoing and upcoming clinical trials.A Mathematical Modeling Approach to Understanding the Effect of Anti-Interleukin Therapy on Eosinophils.Type 2 immunity in tissue repair and fibrosis.Repetitive Intradermal Bleomycin Injections Evokes T Helper Cell 2 Cytokine-driven Pulmonary Fibrosis.A Dataset of 26 Candidate Gene and Pro-Inflammatory Cytokine Variants for Association Studies in Idiopathic Pulmonary Fibrosis: Frequency Distribution in Normal Czech Population.Modulation of pulmonary fibrosis by IL-13Rα2.Drugs and Targets in Fibrosis.Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma.AKT2 Regulates Pulmonary Inflammation and Fibrosis via Modulating Macrophage Activation.Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies.Modeling Idiopathic Pulmonary Fibrosis in Humanized SCID Mice.Epithelial-mesenchymal transition in Crohn's disease.The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis.Novel imaging approaches for small animal models of lung disease (2017 Grover Conference series).Resolution of organ fibrosis.IL-13 induces periostin and eotaxin expression in human primary alveolar epithelial cells: Comparison with paired airway epithelial cells.TRAIL-Dependent Resolution of Pulmonary Fibrosis.Idiopathic Pulmonary Fibrosis (IPF): An OverviewCCR10+ epithelial cells from idiopathic pulmonary fibrosis lungs drive remodeling
P2860
Q26799600-EB455E9D-998B-40B1-99E5-F1EA3DE576BEQ33904342-671895E5-7FBA-4728-BB34-7ED09C8B8849Q34534282-B3734BFA-DD93-405E-96CC-D795051D4EA8Q35086389-69A53BC7-8E63-47EC-957E-12008D667A5EQ35256069-82390B12-0459-44A4-A3FA-145D6B6375DFQ36040475-A6E97F24-29E5-4B16-A17C-16CCCCA3D6AFQ36146139-2D044175-D9C6-448F-89D3-3F7803612F88Q36438280-0E4218A3-58F1-4538-BA02-AD36F505EFEDQ36682162-E55C2BB6-A271-449C-AFF5-691496498CE2Q37026406-BA8B5420-0DB7-44B4-9AF8-AEEC1F5BE351Q37080510-D52D8736-C619-4417-A80D-71E144226E07Q37526117-C1C7ED7A-8A00-4ACE-954B-1EE743F61A19Q38543042-47E97C84-CBF5-461A-AC25-54371D744319Q38634828-4F6B8CF4-657C-421B-BBE0-C00F8DA5789EQ38826634-2551B833-8AC8-4AA2-AE43-1A744C5A7553Q38843261-F5681403-9C2B-4676-A2CD-45C9DFDCA8F3Q38883893-FA685C35-C0C0-497A-921B-AD27C5C322B8Q38918934-C713E1B9-6380-4F1B-BF2F-233B22B5B0CDQ38956376-89577FE6-971F-4A7A-9525-AA124AEEF571Q39330304-4675ED30-60EC-4EC8-98B0-1BE2BD4FC14BQ40067123-8FA01B89-7880-4308-B47A-E9BF7EB82FC5Q40074887-FB61FB0F-A123-448E-A698-2628F4D398A0Q40107399-0DF03B9E-764D-40BE-906A-3BBFC4397748Q42228778-B3F56633-5DF4-4476-B383-DAA6C190D044Q42830623-2244A355-3136-493C-B6C0-D0FE3AFEC9D5Q47119118-48D43A90-AE37-48B9-8096-F8D41EDBA587Q47127150-FCFDA6C0-D5E0-4031-A2C6-F3BAA4A2172BQ47736517-DB13EFAC-B450-4A77-83AA-63230B532DF6Q47901631-AF444944-83CB-4D9B-83B4-32CE702DC2A9Q49603082-04C40395-B93C-4D15-AAB1-2FCF1740E642Q49965391-72BB5386-5649-4D30-9AE1-CCEC99E4E1C8Q50069018-B80361D6-037C-4F33-9A16-06D22EA386AAQ52685723-8D61D159-70B8-447C-8C26-6359BEE33369Q52687459-D465E770-DB13-4892-AC7E-7AD07C114CA2Q54995748-1B0617C3-78AD-48F8-8676-CF4D60A58B28Q55543508-3F2A610F-845A-4001-AA7E-E6A41C82CFA4Q57170607-21033534-337D-4361-867D-5FAEA48978DCQ58710919-57557C64-E670-4806-9CD5-6D804769C61A
P2860
Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeting interleukin-13 with ...... thic pulmonary fibrosis model.
@ast
Targeting interleukin-13 with ...... thic pulmonary fibrosis model.
@en
type
label
Targeting interleukin-13 with ...... thic pulmonary fibrosis model.
@ast
Targeting interleukin-13 with ...... thic pulmonary fibrosis model.
@en
prefLabel
Targeting interleukin-13 with ...... thic pulmonary fibrosis model.
@ast
Targeting interleukin-13 with ...... thic pulmonary fibrosis model.
@en
P2093
P2860
P356
P1476
Targeting interleukin-13 with ...... athic pulmonary fibrosis model
@en
P2093
Ana Lucia Coelho
Cory M Hogaboam
Darryl A Knight
Erica L Herzog
Fernando J Martinez
Huilan Zhang
Kevin R Flaherty
Matthew A Sleeman
P2860
P304
P356
10.1165/RCMB.2013-0342OC
P577
2014-05-01T00:00:00Z